Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the feasibility of using balanced propofol sedation for bronchoscopy. And screen out the optimal balanced propofol sedation compatibility plan.
Balanced propofol sedation (BPS) is a technique proposed and developed by gastroenterologists. In recent years, multiple studies have confirmed that the use of BPS in gastrointestinal endoscopy can not only ensure patient comfort, but also reduce the incidence of respiratory and circulatory suppression. Moreover, the postoperative recovery time is short. Even for non-anesthesiologists applying BPS in gastrointestinal endoscopy , it has high safety.
Compared with gastrointestinal endoscopy, bronchoscopy occupies the respiratory tract and most patients have respiratory system diseases. Therefore, it is more necessary for strict respiratory management and control of patient sedation depth. Traditional midazolam combined with opioid drugs or propofol monosedation cannot effectively meet clinical needs. The excellent sedative and analgesic effects of BPS, as well as its maintenance of respiratory and circulatory functions, make it theoretically very suitable for application in bronchoscopy. However, there is currently a lack of evidence to support the application of BPS in bronchoscopy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| S-M group | Midazolam combines with sufentanil to titrate to moderate sedation for bronchoscopy. |
| |
| S-M-P group | Midazolam and sufentanil combine with low-dose propofol to titrate to deep sedation for bronchoscopy. |
| |
| S-R group | Remazolam combines with sufentanil to titrate to moderate sedation for bronchoscopy. |
| |
| S-R-P group | Remazolam and sufentanil combine with low-dose propofol to titrate to deep sedation for bronchoscopy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Midazolam and sufentanil | Drug | Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Patient satisfaction | The investigator needs to use VAS scores to evaluate satisfaction about sedation feeling when they accepted bronchoscopy. The score from 0 (extremely dissatisfied) to 10 (extremely satisfied). | During bronchoscopy. |
| Clinical satisfaction | The investigator needs to use VAS scores to evaluate satisfaction about doctors and nurses when they carry out the operation. The score from 0 (extremely dissatisfied) to 10 (extremely satisfied). | During bronchoscopy. |
| Patient's recovery time | The investigator needs to record the wake-up time of patients after the end of bronchoscopy. | The end of bronchoscopy (up to 2 hours). |
| Patient's departure time | The investigator needs to record the patient's departure time after the end of bronchoscopy. | The end of bronchoscopy (up to 2 hours). |
| Measure | Description | Time Frame |
|---|---|---|
| Induction time | Time from administering sedative and analgesic drugs to titration with propofol until MOAA/S 2-3 points. | Before bronchoscopy. |
| Drug dosage | Induced, maintenance and total dose of midazolam, propofol. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Population undergoing bronchoscopy examination at Qingdao University Affiliated Hospital from December 2023 to January 2014.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital of Qingdao University | Shandong | Qingdao | China |
Not provided
| ID | Term |
|---|---|
| D008874 | Midazolam |
| D017409 | Sufentanil |
| D015742 | Propofol |
| ID | Term |
|---|---|
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
| Midazolam, sufentanil and propofol | Drug | Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol. |
|
| Remazolam and sufentanil. | Drug | Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani. |
|
| Remazolam, sufentanil and propofol | Drug | Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol. |
|
| Before bronchoscopy and during bronchoscopy. |
| Additional frequency of propofol during bronchoscopy | Additional frequency of propofol during bronchoscopy. | During bronchoscopy. |
| Additional frequency of 2% lidocaine during bronchoscopy | Additional frequency of 2% lidocaine during bronchoscopy. | During bronchoscopy. |
| Additional dosage of 2% lidocaine during bronchoscopy | Additional dosage of 2% lidocaine during bronchoscopy. | During bronchoscopy. |
| Additional dosage of propofol during bronchoscopy | Additional dosage of propofol during bronchoscopy. | During bronchoscopy. |
| Patient response score during bronchoscopy | Researcher used the Behavioral Pain Scale for non intubated patients (BPS-NI) to assess their response scores. The tool consists of 3 behavioral domains: facial expressions, movements, and vocalization. The total BPS-IN value can range from 3 (no pain) to 12 (most pain). | During bronchoscopy. |
| Adverse reactions during bronchoscopy | Record the number of occurrences of hypotension, hypertension, tachycardia, bradycardia, arrhythmias, hypoxemia, apnea, coughing (no wheezing during continuous coughing, considered as one coughing), and physical activity (non directive limb activity) during bronchoscopy. After fully awake, researcher 2 used the VAS score for adverse reactions during the resuscitation process, such as dizziness, pain, nausea, breathing difficulties, etc. | During bronchoscopy |
| Adverse reactions after fully awake | After fully awake, researcher used the VAS score for adverse reactions during the resuscitation process, such as dizziness, pain, nausea, breathing difficulties, etc. The score from 0 (no uncomfortable) to 10 (extremely uncomfortable). | The end of bronchoscopy (up to 2 hours). |
| Patient's anxiety/depression state | Researcher used the Patient Health Questionnaire-8 (PHQ-8) to assess Patient's anxiety/depression state. The total score range of PHQ-8 is 0-24. No depressive symptoms on a score of 0-4, mild on a score of 5-9, moderate on a score of 10-14, and severe on a score of 15 or above. | Day before bronchoscopy. 1, 3, 7, and 14 days after bronchoscopy. |
| D006571 | Heterocyclic Compounds |
| D005283 | Fentanyl |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |